Publications by authors named "Chok G Chan"
Article Synopsis
- The SGLT2 inhibitor empagliflozin is funded in New Zealand for type 2 diabetes patients with high cardiovascular risk and elevated HbA1c levels.
- Research shows that SGLT2 inhibitors significantly lower risks of serious conditions like cardiovascular death, heart failure, kidney dysfunction, and related diseases.
- There is a compelling argument for expanding the funding of SGLT2 inhibitors to help patients with heart failure or kidney issues, even if they do not have diabetes, potentially benefiting a larger population.
